You searched for Heslop - Baylor College of Medicine Blog Network

Election to the National Academy of Medicine recognizes outstanding professional achievement and commitment to service.

Long-term survival supports the potential benefit of CAR T cell therapy to treat solid tumors

February 27, 2025 CAR T cell therapy, Clinical Trials, disease free, longest survival, neuroblastoma, Research, solid tumors

An 18-year survivor of neuroblastoma is believed to represent the longest reported remission to date in a patient treated with chimeric antigen receptor (CAR) T cell therapy.

Pre- and post-infusion three-dimensional imaging shows that infused GPC3 CAR T cells induce significant antitumor responses in patients.

From The Labs

From bench to bedside and back: CAR T cells armed with IL-15 show promise in treating solid cancers

January 28, 2025 cancer treatment, CAR T cells, Clinical Trials, IL-15, Research, solid tumors

Researchers relate their journey to finding a promising method to address CAR T cell challenges in treating solid tumors.

From The Labs

Baylor College of Medicine receives more than $17 million from CPRIT

August 22, 2024 Cancer, CPRIT awards, Research

The CPRIT awards support developmental research focusing on promising new insights into cancer treatment and innovative core facilities.

From The Labs

CAR T cell therapy for pediatric brain cancer warrants further study

June 18, 2024 C7R, CAR T cells, clinical trial, Glioma, pediatric brain cancer, Research

This study shows that this therapy can effectively get to the tumor, and the addition of C7R safely augments antitumor activity.

Left: Matt Rea receiving CD19 CAR-T cells from Dr. Carlos Ramos and Dr. Barbara Savoldo. Right: Matt Rea with his identical twin brother Will Rea.

Momentum

Following up with long-term survivor of CAR T cell therapy

June 4, 2024 Cancer, CAR-T, Non-Hodgkin’s lymphoma

Non-Hodgkin’s lymphoma patient Matt Rea flew to Houston to receive CD19 CAR-T cells from his identical twin brother Will Rea.

From The Labs

CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in phase I clinical trial

May 21, 2024 CARTcell therapy, HEROS clinical trial, Research, sarcoma

The HEROS 2.0 trial showed that this therapeutic approach is safe and is associated with clinical benefit.

From The Labs

CAR T cell therapy for T cell lymphoma shows promise in phase I trial

January 19, 2024 cancer therapy, CAR Tcells, CD5, clinical trial, Research, T cell lymphoma

A first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of anti-tumor efficacy and safety.